How much funding has Amylyx Pharmaceuticals raised?

Amylyx Pharmaceuticals has raised $197.3M in total funding, most recently a Series A round.

Who are Amylyx Pharmaceuticals's investors?

Amylyx Pharmaceuticals's investors include Morningside Group, Viking Global, ALS Investment Fund, Bain Capital Life Sciences.

When was Amylyx Pharmaceuticals founded?

Amylyx Pharmaceuticals was founded in 2013.

Where is Amylyx Pharmaceuticals headquartered?

Amylyx Pharmaceuticals is headquartered in Cambridge, Massachusetts, United States.

What industry is Amylyx Pharmaceuticals in?

Amylyx Pharmaceuticals operates in Healthcare, Biotech.

Amylyx Pharmaceuticals

IPO

Public · Cambridge, United States · Founded 2013 · $197.3M raised

Healthcare

Biotech

Headquarters: Cambridge, Massachusetts
Founded: 2013
Business Model: B2B
Website: amylyx.com

Total Funding: $197.3M
Last Round: $5.0M Series AJul 2021
Rounds: 4
Type: Public

About

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2013 by Josh Cohen and Justin Klee at Brown University, headquartered in Cambridge, Massachusetts. The company is dedicated to developing novel therapies for diseases with high unmet needs, with a pipeline spanning ALS, Wolfram syndrome, post-bariatric hypoglycemia, and congenital hyperinsulinism. Amylyx completed its IPO on NASDAQ in January 2022 and has advanced multiple investigational therapies through Phase 2 and Phase 3 clinical trials, backed by rigorous science and deep engagement with patient communities.

Summary

Amylyx Pharmaceuticals is a Healthcare company based in Cambridge, United States, founded in 2013. It has raised $197.3M in total across 4 rounds, most recently a $5.0M Series A round in Jul 2021. Investors include Morningside Group, Viking Global and ALS Investment Fund.